Greisshammer M, Saydam G, Palandri F, et al. Ruxolitinib fort he treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. EHA 2017, abstract S784.
Meta-analyse bevestigt hoge remissiepercentage na CAR T-celtherapie bij B-ALL
apr 2021 | Leukemie